Malinee Thanee

Dr. Malinee Thanee

Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
+1

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
SASupakan Amontailak
Supakan Amontailak
ATAttapol Titapun
Attapol Titapun
AJapinya jusakul
apinya jusakul
RTRaynoo Thanan
Raynoo Thanan
PKPhongsaran Kimawaha
Phongsaran Kimawaha
ATAnchalee Techasen
Anchalee Techasen
Background: The epithelial malignant tumor known as cholangiocarcinoma (CCA) is most commonly found in Southeast Asia, particularly in northeastern Thailand. Previous research has indicated that the overexpression of acyl-CoA synthetase long-chain family member 4 (ACSL4), solute carrier family 7 member 11 (SLC7A11), and ChaC glutathione-specific γ-glutamylcyclotransferase (CHAC1) as ferroptosis-related proteins is associated with poorer prognosis in several cancers. The role of these three proteins in CCA is still unclear. The present study aimed to investigate the expression levels of ACSL4, SLC7A11, and CHAC1, all potential ferroptosis biomarkers, in CCA. Methods: The ACSL4, SLC7A11, and CHAC1 protein expression levels in 137 CCA tissues were examined using immunohistochemistry, while 61 CCA serum samples were evaluated using indirect ELISA. The associations between the expression levels of ACSL4, SLC7A11, and CHAC1 and patient clinicopathological data were evaluated to determine the clinical significance of these proteins. Results: The expression levels of ACSL4, SLC7A11, and CHAC1 were assessed in CCA tissues. A significant association was observed between high ACSL4 levels and extrahepatic CCA, tumor growth type, and elevated alanine transferase (ALT). There was also a positive association between elevated SLC7A11 levels and tumor growth type. Additionally, the upregulation of CHAC1 was significantly associated with a shorter survival time in patients. High levels of ACSL4 and SLC7A11 in CCA sera were both significantly associated with advanced tumor stages and abnormal liver function test results, indicating that they could be used as a reliable prognostic biomarker panel in patients with CCA. Conclusions: The results of the present study demonstrated that the upregulation of ACSL4, SLC7A11, and CHAC1 could be used as a valuable biomarker panel for predicting prognosis parameters in CCA. Furthermore, ACSL4 and SLC7A11 could potentially serve as complementary markers for improving the accuracy of prognosis prediction when CCA sera is used. These less invasive biomarkers could facilitate effective treatment planning.

10 June 2022 in Frontiers in Public Health
Verified
Journal Article
Open access
SKSupinda Koonmee
Supinda Koonmee
SSSakkarn Sangkhamanon
Sakkarn Sangkhamanon
PIPiyapharom Intarawichian
Piyapharom Intarawichian
CAChaiwat Aphivatanasiri
Chaiwat Aphivatanasiri
WKWaritta Kunprom
Waritta Kunprom
MTMalinee Thanee
Malinee Thanee
Cholangiocarcinoma (CCA) is the most prevalent malignancy in Thailand, with unfortunate late diagnosis and frequent metastatic disease outcomes. An accurate tissue diagnosis is the first and most important step in the treatment of CCA. Tissue quality and preservation during the pre-analytical phase play major roles in the proper histological evaluation and potential biomarker testing. This study evaluated the impact of using the “Cholangiocarcinoma Screening and Care Program (CASCAP)” container, as an innovative tool to address pre-analytical challenges faced by pathology laboratories in Thailand. This is a comparison study examining the quality of CCA specimens using the CASCAP container vs. the conventional method, using hematoxylin and eosin (H&E) and immunohistochemistry (IHC). CCA tissue quality using the CASCAP container significantly reduced artifact deposition while improving the cellular structure and nuclear and cytoplasmic morphologies. The immunohistochemical expression of cytokeratin 19 (CK19), a prognostic marker in CCA, significantly improved in the CASCAP container group in comparison with the conventional method. This innovation is proven to significantly enhance the CCA tissue quality diagnostics and prognostic biomarker testing, hence improving overall cancer care, diagnosis, and treatment in Thailand.

1 July 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
STSutheemon Techa-Ay
Sutheemon Techa-Ay
SWSasithorn Watcharadetwittaya
Sasithorn Watcharadetwittaya
RDRaksawan Deenonpoe
Raksawan Deenonpoe
KIKitti Intuyod
Kitti Intuyod
WKWaleeporn Kaewlert
Waleeporn Kaewlert
MTMalinee Thanee
Malinee Thanee
Cholangiocarcinoma (CCA) is a prevalent bile duct cancer with limited treatment options. Cisplatin-based chemotherapy is a common approach, but response rates vary. Recently, chromosome aberrations have emerged as predictors of chemotherapy response in various malignancies. This study aimed to identify chromosomal aberrations associated with cisplatin response in CCA. A histoculture drug response assay was conducted on 20 fresh CCA tissues to determine cisplatin sensitivity. In parallel, chromosome aberration analysis was performed using chromosome microarray. Using chromosome microarray analysis on 20 CCA samples, we found distinct chromosomal aberration patterns between cisplatin responders and non-responders. Gains in 18q and 20q, and losses in 1p and 8p were more common in non-responders. Conversely, the responders exhibited gains in 8q and losses in 16q. Our heatmap analysis of log-2 ratio demonstrated difference in various chromosomes including 2, 3p, 5q, 6q, 7, 9p, 11q, 14q, 15q, 18q, 20q, and 22q between the response and the non-response to cisplatin. Further analysis using machine learning with random forest model identified genes like NCOA3, TPK1, CEP57L1, DEPDC5, and PLXNA4 as potential predictors of cisplatin response. Validation in a separate cohort of 33 CCA samples confirmed the association of NCOA3 and DEPDC5 with cisplatin response. Our findings suggest that chromosomal aberrations and specific genes may predict cisplatin response in CCA, potentially guiding personalized treatment strategies.

7 January 2026 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
ALAdjima Luechine
Adjima Luechine
ATAnchalee Techasen
Anchalee Techasen
JPJutarop Phetcharaburanin
Jutarop Phetcharaburanin
SDSukhonthip Ditcharoen
Sukhonthip Ditcharoen
WLWatcharin Loilome
Watcharin Loilome
MTMalinee Thanee
Malinee Thanee
Gastrointestinal (GI) malignancies exhibit significant global variations in incidence and mortality. Late diagnosis remains a major challenge especially ga

4 September 2023
Verified
Book Chapter
Closed access
PDF file
SKSupinda Koonmee
Supinda Koonmee
PSPrakasit Sa-Ngiamwibool
Prakasit Sa-Ngiamwibool
CAChaiwat Aphivatanasiri
Chaiwat Aphivatanasiri
WKWaritta Kunprom
Waritta Kunprom
PIPiyapharom Intarawichian
Piyapharom Intarawichian
MTMalinee Thanee
Malinee Thanee

8 April 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
STSutheemon Techa-Ay
Sutheemon Techa-Ay
SWSasithorn Watcharadetwittaya
Sasithorn Watcharadetwittaya
RDRaksawan Deenonpoe
Raksawan Deenonpoe
PSPrakasit Sa-Ngiamwibool
Prakasit Sa-Ngiamwibool
CPChanita Panwoon
Chanita Panwoon
MTMalinee Thanee
Malinee Thanee
Cholangiocarcinoma (CCA) is an epithelial bile duct cancer frequently found at an advanced stage, leading to poor response to current therapies. Although gemcitabine (GEM) and cisplatin (CIS) are the current gold-standard for treating unresectable CCA, GEM resistance often occurs. To predict the response to GEM, we evaluated chromosomal aberrations using a chromosome microarray, and their association with GEM response by histoculture drug response assay. Our findings revealed principal component analysis and orthogonal partial-least square discriminant analysis cross validated score plot between response and non-response groups were different. Different signature patterns of chromosomes between response and non-response groups analyzed by heatmap analysis identified 34 regions of 15 chromosomes. An increased signal in responders and a decreased signal in non-responders were found in regions 4q32.1, 5q12.3, 10q21.3, 11p11.2, 11q14.2, 16p11.2, 17q22, 21q21.3 and 22q12.3. In contrast, a high signal in non-responders and low signal in responders were seen in regions 2q37.2, 11q14.1, 16q22.3 and 16q23.3. High signal of CDH13 and TENM4 were demonstrated in GEM non-response, while a high CWC27 signal was noted in GEM response. This signature pattern could provide the knowledge to improve a predictive biomarker for GEM response, benefitting for individual CCA patient management and chemotherapeutic selection.